Categorynews

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Markets 2017-2018 & 2019-2025 – ResearchAndMarkets.com

July 16, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025” report has been added to ResearchAndMarkets.com’s offering.

The report predicts the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market to grow with a CAGR of 11.6% over the forecast period from 2019-2025.

The report on the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025. The study on paroxysmal nocturnal hemoglobinuria (PNH) treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter’s five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market over the period of 2017 to 2025. Further, Growth Matrix in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • The rising number of blood and bone marrow related disorders
  • Development in stem cell research

2) Restraints

  • High costs associated with medical treatment and adverse side effects with existing treatments

3) Opportunities

  • The unmet demand for drugs in developing countries

Key Topics Covered:

1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

2. Executive Summary

2.1. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Highlights

2.2. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Projection

2.3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Regional Highlights

3. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter’s Five Forces Analysis

3.4. Growth Matrix Analysis

3.4.1. Growth Matrix Analysis by Diagnostic Test

3.4.2. Growth Matrix Analysis by Treatment

3.4.3. Growth Matrix Analysis by Region

3.5. Value Chain Analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment Market

4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Macro Indicator Analysis

5. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test

5.1. Complete Blood Count Test (CBC)

5.2. Lactate Dehydrogenase Test (LDH)

5.3. Bone Marrow Examination

5.4. Urine Test for Hemosiderin

5.5. Flow Cytometry

5.6. Other Tests

6. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment

6.1. Medication

6.2. Stem Cell Transplant

6.3. Blood Transfusion

7. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Region 2019-2025

7.1. North America

7.1.1. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test

7.1.2. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment

7.1.3. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Country

7.2. Europe

7.3. Asia-Pacific

7.4. RoW

8. Company Profiles and Competitive Landscape

8.1. Competitive Landscape in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market

8.2. Companies Profiles

8.2.1. F. Hoffmann-La Roche AG

8.2.2. Akari Therapeutics

8.2.3. Alexion Pharmaceuticals, lnc.

8.2.4. Ra Pharmaceuticals

8.2.5. Novartis AG

8.2.6. Alnylam Pharmaceuticals, Inc.

8.2.7. Apellis Pharmaceuticals

8.2.8. Achillion Pharmaceuticals

8.2.9. Regeneron Pharmaceuticals, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/oejwlq

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Hematological Drugs